Company: NCEL
Filing Date: 2025-03-31
Form Type: F-4/A
Source: 0001213900-25-026428
Chunk: 876

Company: NewcelX Ltd.
Filing Date: 2025-03-31
Form: F-4/A
Chunk 876
---
 cash balance of NLS following its most recent successful financing transaction, the parties currently estimate the fully diluted share split at the Closing will be 80% to the Company’s stakeholders and 20% to NLS stakeholders. The boards of directors of the Company and NLS have unanimously approved this transaction and expect it to close in January 2025, pending approval of each of NLS’ and the Company’s shareholders, as well as other customary closing conditions, including Nasdaq approval. Annex G-62 Annex H VOTE ON INTERNET Go to http://www.vstocktransfer.com/proxy Click on Proxy Voter Login and log-on using the below control number. Voting will be open until 11:59 p.m. (Eastern Time) [•] 2025. CONTROL 

# VOTE BY EMAIL SPECIMEN Mark, sign and date your proxy card and send it 1 MAIN STREET to vote@vstocktransfer.com. ANYWHERE PA 99999-9999 VOTE BY MAIL Mark, sign and date your proxy card and return it in the envelope we have provided. Please Vote, Sign, Date and Return Promptly in the Enclosed Envelope. Extraordinary Meeting of Shareholders Proxy Card - NLS Pharmaceutics Ltd. [NTD: Proxy Card to be updated/reviewed by vstocktransfer.] DETACH PROXY CARD HERE TO VOTE BY MAIL The Board of Directors recommends a vote “FOR” all listed Proposals 1. Approval of the Merger Agreement on an advisory basis The board proposes to approve the Merger Agreement, that the Company has entered into on 4 November 2024 according to which it will merge with Kadimastem, in the sense of an advisory vote. FOR AGAINST ABSTAIN 2. Ordinary Share Capital Increase re Contribution of the Kadimastem Shares The board proposes to increase the share capital of the Company to implement the merger with Kadimastem, by way of an ordinary capital increase, by a maximum of CHF [•] (i.e., via the issuance of a maximum of [•] fully paid-in registered shares in the Company with a nominal value of CHF 0.03 each (the “Additional A Shares”)) and to issue these Additional A Shares at the terms listed in the Invitation. FOR AGAINST ABSTAIN 3. Ordinary Share Capital Increase re preferred shares The board proposes to increase the share capital of the Company pursuant to the terms of the PIPE SPA, by way of an ordinary capital increase,